Srinivas Sridhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Srinivas Sridhar has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Wentao T. Lu
Department of Physics and Electronic Materials Research Institute, Northeastern University, Boston, Massachusetts 02115, USA
7 shared publications Y. J. Huang
6 shared publications- Dattatri Nagesha
Northeastern University
5 shared publications P. Vodo
Department of Physics Electronic Materials Research Institute Northeastern University 02115 Boston Massachusetts
5 shared publications- Anne L. van de Ven
Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030, USA
4 shared publications W. T. Lu
4 shared publications
Latest Publications
- Open Access
- 1 April 2018
- Published by Elsevier in Data in Brief
- Vol. 17, 393-396
Dataset on a 173 region awake resting state quantitative cerebral blood volume rat brain atlas and regional changes to cerebral blood volume under isoflurane anesthetization and CO2 challenge
- 1 April 2018
- Published by Elsevier in Data in Brief
- Vol. 17, 393-396
Open AccessDataset on a 173 region awake resting state quantitative cerebral blood volume rat brain atlas and regional changes to cerebral blood volume under isoflurane anesthetization and CO2 challenge
- Open Access
- 1 March 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13 (T-NANO 201) , 59-61
In vitro analysis of PARP inhibitor nanoformulations
PARP-l is a DNA repair protein that plays a role in a number of repair pathways and also helps in transcriptional regulation; thus PARP inhibitors (PARPi), such as olaparib and BMN-673, act by inhibiting DNA damage repair. This leads to an accumulation of deleterious mutations leading to genetic instability as a result of a number of cell replications. Currently, olaparib is only available in an oral form and has poor bioavailability, consequently leading to poor accumulation in the tumor due to first-pass metabolism. Therefore, in the present study, an injectable nanoparticle formulation of olaparib was created that offers a delivery route in which the drug would be fully bioavailable in the vasculature, suggesting greater tumor accumulation. Our results illustrated that injectable nanoformulations of olaparib and BMN-673, a next generation PARPi, could be developed, and an efficacy test indicated that BMN-673 is a much more potent PARPi than olaparib. The success of these molecular inhibitors as a monotherapy in inhibiting colony formation suggests enhanced efficacy of these treatments in combination with other therapies, even in tumors which have developed resistance.
- 1 March 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13 (T-NANO 201) , 59-61
Open AccessIn vitro analysis of PARP inhibitor nanoformulations
PARP-l is a DNA repair protein that plays a role in a number of repair pathways and also helps in transcriptional regulation; thus PARP inhibitors (PARPi), such as olaparib and BMN-673, act by inhibiting DNA damage repair. This leads to an accumulation of deleterious mutations leading to genetic instability as a result of a number of cell replications. Currently, olaparib is only available in an oral form and has poor bioavailability, consequently leading to poor accumulation in the tumor due to first-pass metabolism. Therefore, in the present study, an injectable nanoparticle formulation of olaparib was created that offers a delivery route in which the drug would be fully bioavailable in the vasculature, suggesting greater tumor accumulation. Our results illustrated that injectable nanoformulations of olaparib and BMN-673, a next generation PARPi, could be developed, and an efficacy test indicated that BMN-673 is a much more potent PARPi than olaparib. The success of these molecular inhibitors as a monotherapy in inhibiting colony formation suggests enhanced efficacy of these treatments in combination with other therapies, even in tumors which have developed resistance.
- 1 December 2017
- Published by Elsevier in NeuroImage
- Vol. 163, 24-33
Quantitative vascular neuroimaging of the rat brain using superparamagnetic nanoparticles: New insights on vascular organization and brain function
- 1 December 2017
- Published by Elsevier in NeuroImage
- Vol. 163, 24-33
Quantitative vascular neuroimaging of the rat brain using superparamagnetic nanoparticles: New insights on vascular organization and brain function
- 2 February 2017
- Published by Springer Nature
- Vol. 1530, 337-342
Generation of Dose–Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations
Poly(ADP-ribose) polymerase (PARP) inhibitors that target DNA damage repair pathways in cancer cells are increasingly attractive for treating several cancers. Determining the half maximal inhibitory concentration (IC50) of these molecular inhibitors in cell lines is crucial for further dosing for in vivo experiments. Typically these in vitro assays are conducted for 24–72 h; however, PARP inhibitors exhibit cytotoxicity based on the inability to repair DNA damage and thus the accumulation of deleterious mutations takes place over longer times. Therefore, in order to determine a relevant dose response, the time frame of the assay must be modified to account for the time required for the cells to exhibit effects from the treatment. Here, we describe two techniques for generating both short- and long-term dose–response curves for both free PARP inhibitors and nanoparticle formulations of these drugs.
- 2 February 2017
- Published by Springer Nature
- Vol. 1530, 337-342
Generation of Dose–Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations
Poly(ADP-ribose) polymerase (PARP) inhibitors that target DNA damage repair pathways in cancer cells are increasingly attractive for treating several cancers. Determining the half maximal inhibitory concentration (IC50) of these molecular inhibitors in cell lines is crucial for further dosing for in vivo experiments. Typically these in vitro assays are conducted for 24–72 h; however, PARP inhibitors exhibit cytotoxicity based on the inability to repair DNA damage and thus the accumulation of deleterious mutations takes place over longer times. Therefore, in order to determine a relevant dose response, the time frame of the assay must be modified to account for the time required for the cells to exhibit effects from the treatment. Here, we describe two techniques for generating both short- and long-term dose–response curves for both free PARP inhibitors and nanoparticle formulations of these drugs.
- Open Access
- 1 January 2017
- Published by Ivyspring International Publisher in Theranostics
- Vol. 7 (17) , 4340-4349
Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we sought to develop new delivery systems in the form of an implant loaded with Talazoparib for localized, slow and sustained release of the drug at the tumor site in Brca1-deficient breast cancer. Poly(lactic-co-glycolic acid) (PLGA) implants (0.8 mm diameter) loaded with subclinical dose (25 or 50 µg) Talazoparib were fabricated and characterized. In vitro studies with Brca1-deficient W780 and W0069 breast cancer cells were conducted to test sensitivity to PARP inhibition. The in vivo therapeutic efficacy of Talazoparib implants was assessed following a one-time intratumoral injection in Brca1Co/Co;MMTV-Cre;p53+/- mice and compared to drug-free implants and oral gavage. Immunohistochemistry studies were performed on tumor sections using PCNA and γ-H2AX staining. Sustained release of Talazoparib was observed over 28 days in vitro. Mice treated with Talazoparib implants showed statistically significant tumor growth inhibition compared to those receiving drug-free implants or free Talazoparib orally. Talazoparib implants were well-tolerated at both drug doses and resulted in less weight loss than oral gavage. PARP inhibition in mice treated with Talazoparib implants significantly increased double-stranded DNA damage and decreased tumor cell proliferation as shown by PCNA and γ-H2AX staining as compared to controls. These results demonstrate that localized and sustained delivery of Talazoparib via implants has potential to provide superior treatment outcomes at sub-clinical doses with minimal toxicity in patients with BRCA1 deficient tumors.
- 1 January 2017
- Published by Ivyspring International Publisher in Theranostics
- Vol. 7 (17) , 4340-4349
Open AccessSustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we sought to develop new delivery systems in the form of an implant loaded with Talazoparib for localized, slow and sustained release of the drug at the tumor site in Brca1-deficient breast cancer. Poly(lactic-co-glycolic acid) (PLGA) implants (0.8 mm diameter) loaded with subclinical dose (25 or 50 µg) Talazoparib were fabricated and characterized. In vitro studies with Brca1-deficient W780 and W0069 breast cancer cells were conducted to test sensitivity to PARP inhibition. The in vivo therapeutic efficacy of Talazoparib implants was assessed following a one-time intratumoral injection in Brca1Co/Co;MMTV-Cre;p53+/- mice and compared to drug-free implants and oral gavage. Immunohistochemistry studies were performed on tumor sections using PCNA and γ-H2AX staining. Sustained release of Talazoparib was observed over 28 days in vitro. Mice treated with Talazoparib implants showed statistically significant tumor growth inhibition compared to those receiving drug-free implants or free Talazoparib orally. Talazoparib implants were well-tolerated at both drug doses and resulted in less weight loss than oral gavage. PARP inhibition in mice treated with Talazoparib implants significantly increased double-stranded DNA damage and decreased tumor cell proliferation as shown by PCNA and γ-H2AX staining as compared to controls. These results demonstrate that localized and sustained delivery of Talazoparib via implants has potential to provide superior treatment outcomes at sub-clinical doses with minimal toxicity in patients with BRCA1 deficient tumors.
- Open Access
- 18 November 2015
- Published by Wiley in International Journal of Optics
- Vol. 2015, 1-6
A Novel Coupled Resonator Photonic Crystal Design in Lithium Niobate for Electrooptic Applications
High-aspect-ratio photonic crystal air-hole fabrication on bulk Lithium Niobate (LN) substrates is extremely difficult due to its inherent resistance to etching, resulting in conical structures and high insertion losses. Here, we propose a novel coupled resonator photonic crystal (CRPC) design, combining a coupled resonator approach with that of Bragg gratings. CRPC design parameters were optimized by analytical calculations and FDTD simulations. CRPC structures with optimized parameters were fabricated and electrooptically tested on bulk LN annealed proton exchange waveguides. Low insertion loss and large electrooptic effect were observed with the fabricated devices, making the CRPC design a promising structure for electrooptic device applications.
- 18 November 2015
- Published by Wiley in International Journal of Optics
- Vol. 2015, 1-6
Open AccessA Novel Coupled Resonator Photonic Crystal Design in Lithium Niobate for Electrooptic Applications
High-aspect-ratio photonic crystal air-hole fabrication on bulk Lithium Niobate (LN) substrates is extremely difficult due to its inherent resistance to etching, resulting in conical structures and high insertion losses. Here, we propose a novel coupled resonator photonic crystal (CRPC) design, combining a coupled resonator approach with that of Bragg gratings. CRPC design parameters were optimized by analytical calculations and FDTD simulations. CRPC structures with optimized parameters were fabricated and electrooptically tested on bulk LN annealed proton exchange waveguides. Low insertion loss and large electrooptic effect were observed with the fabricated devices, making the CRPC design a promising structure for electrooptic device applications.
- Open Access
- 1 December 2014
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10, 23-30
Essential components of a successful doctoral program in nanomedicine
Essential components of a successful doctoral program in nanomedicine Anne L van de Ven,1,2 Mary H Shann,3 Srinivas Sridhar1,2 1Nanomedicine Science and Technology Center, 2Department of Physics, Northeastern University, Boston, MA, USA; 3School of Education, Boston University, Boston, MA, USA The Nanomedicine program at Northeastern University provides a unique interdisciplinary graduate education that combines experiential research, didactic learning, networking, and outreach. Students are taught how to apply nanoscience and nanotechnology to problems in medicine, translate basic research to the development of marketable products, negotiate ethical and social issues related to nanomedicine, and develop a strong sense of community involvement within a global perspective. Since 2006, the program has recruited 50 doctoral students from ten traditional science, technology, and engineering disciplines to participate in the 2-year specialization program. Each trainee received mentoring from two or more individuals, including faculty members outside the student’s home department and faculty members at other academic institutions, and/or clinicians. Both students and faculty members reported a significant increase in interdisciplinary scholarly activities, including publications, presentations, and funded research proposals, as a direct result of the program. Nearly 90% of students graduating with a specialization in nanomedicine have continued on to careers in the health care sector. Currently, 43% of graduates are performing research or developing products that directly involve nanomedicine. This article identifies some key elements of the Nanomedicine program, describes how they were implemented, and reports on the metrics of success.Keywords: nanomedicine, IGERT, nanotechnology, nanoscience, education, graduate training
- 1 December 2014
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10, 23-30
Open AccessEssential components of a successful doctoral program in nanomedicine
Essential components of a successful doctoral program in nanomedicine Anne L van de Ven,1,2 Mary H Shann,3 Srinivas Sridhar1,2 1Nanomedicine Science and Technology Center, 2Department of Physics, Northeastern University, Boston, MA, USA; 3School of Education, Boston University, Boston, MA, USA The Nanomedicine program at Northeastern University provides a unique interdisciplinary graduate education that combines experiential research, didactic learning, networking, and outreach. Students are taught how to apply nanoscience and nanotechnology to problems in medicine, translate basic research to the development of marketable products, negotiate ethical and social issues related to nanomedicine, and develop a strong sense of community involvement within a global perspective. Since 2006, the program has recruited 50 doctoral students from ten traditional science, technology, and engineering disciplines to participate in the 2-year specialization program. Each trainee received mentoring from two or more individuals, including faculty members outside the student’s home department and faculty members at other academic institutions, and/or clinicians. Both students and faculty members reported a significant increase in interdisciplinary scholarly activities, including publications, presentations, and funded research proposals, as a direct result of the program. Nearly 90% of students graduating with a specialization in nanomedicine have continued on to careers in the health care sector. Currently, 43% of graduates are performing research or developing products that directly involve nanomedicine. This article identifies some key elements of the Nanomedicine program, describes how they were implemented, and reports on the metrics of success.Keywords: nanomedicine, IGERT, nanotechnology, nanoscience, education, graduate training
- Open Access
- 28 August 2014
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 74 (2) , 431-441
Quantitative contrast‐enhanced MRI with superparamagnetic nanoparticles using ultrashort time‐to‐echo pulse sequences
Purpose: Conventional MRI using contrast agents is semiquantitative because it is inherently sensitive to extravoxular susceptibility artifacts, field inhomogeneity, partial voluming, perivascular effects, and motion/flow artifacts. Herein we demonstrate a quantitative contrast‐enhanced MRI technique using ultrashort time‐to‐echo pulse sequences for measuring clinically relevant concentrations of ferumoxytol, a superparamagnetic iron oxide nanoparticle contrast agent with high sensitivity and precision in vitro and in vivo.Methods: The method achieves robust, reproducible results by using rapid signal acquisition at ultrashort time‐to‐echo (UTE) to produce positive contrast images with pure T1 weighting and little T2* decay. The spoiled gradient echo equation is used to transform UTE intensities directly into concentration using experimentally determined relaxivity constants and image acquisition parameters.Results: A multiparametric optimization of acquisition parameters revealed an optimal zone capable of producing high‐fidelity measurements. Clinically relevant intravascular concentrations of ferumoxytol were measured longitudinally in mice with high sensitivity and precision (∼7.1% error). MRI measurements were independently validated by elemental iron analysis of sequential blood draws. Automated segmentation of ferumoxytol concentration yielded high quality three‐dimensional images for visualization of perfusion.Conclusions: This ability to longitudinally quantify blood pool CA concentration is unique to quantitative UTE contrast‐enhanced (QUTE‐CE) MRI and makes QUTE‐CE MRI competitive with nuclear imaging. Magn Reson Med 74:431–441, 2015.
- 28 August 2014
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 74 (2) , 431-441
Open AccessQuantitative contrast‐enhanced MRI with superparamagnetic nanoparticles using ultrashort time‐to‐echo pulse sequences
Purpose: Conventional MRI using contrast agents is semiquantitative because it is inherently sensitive to extravoxular susceptibility artifacts, field inhomogeneity, partial voluming, perivascular effects, and motion/flow artifacts. Herein we demonstrate a quantitative contrast‐enhanced MRI technique using ultrashort time‐to‐echo pulse sequences for measuring clinically relevant concentrations of ferumoxytol, a superparamagnetic iron oxide nanoparticle contrast agent with high sensitivity and precision in vitro and in vivo.Methods: The method achieves robust, reproducible results by using rapid signal acquisition at ultrashort time‐to‐echo (UTE) to produce positive contrast images with pure T1 weighting and little T2* decay. The spoiled gradient echo equation is used to transform UTE intensities directly into concentration using experimentally determined relaxivity constants and image acquisition parameters.Results: A multiparametric optimization of acquisition parameters revealed an optimal zone capable of producing high‐fidelity measurements. Clinically relevant intravascular concentrations of ferumoxytol were measured longitudinally in mice with high sensitivity and precision (∼7.1% error). MRI measurements were independently validated by elemental iron analysis of sequential blood draws. Automated segmentation of ferumoxytol concentration yielded high quality three‐dimensional images for visualization of perfusion.Conclusions: This ability to longitudinally quantify blood pool CA concentration is unique to quantitative UTE contrast‐enhanced (QUTE‐CE) MRI and makes QUTE‐CE MRI competitive with nuclear imaging. Magn Reson Med 74:431–441, 2015.
- 1 October 2013
- Published by Elsevier in Nano Today
- Vol. 8 (5) , 454-460
Nanoparticles for cancer imaging: The good, the bad, and the promise
- 1 October 2013
- Published by Elsevier in Nano Today
- Vol. 8 (5) , 454-460
Nanoparticles for cancer imaging: The good, the bad, and the promise